
    
      The study will be conducted at multiple centers. A total of 42 male and female panic disorder
      patients will be studied. The first 6 subjects will receive Staccato Alprazolam 1 mg open
      label to validate the dose selection. The remaining 36 subjects will be treated with either
      Staccato Alprazolam at the chosen dose; or with Staccato Placebo in a double blind,
      randomized order.
    
  